Noom announced the Noom Band on Monday at the HLTH 2026 conference in Las Vegas, a wearable that will be bundled into its enterprise obesity care programs at no additional upfront cost to employer and health plan clients when it launches in early 2027. The device, powered by Sensor Bio's sensors, is designed to feed continuous data on sleep, activity, heart rate, heart rate variability and SpO2 directly into Noom's behavior-change programs, filling what CEO Geoff Cook called a major data gap in the company's metabolic health offerings.

Noom's Strategic Shift: Introducing the Noom Band

The launch marks the latest step in Noom's evolution from a consumer weight-loss app into a clinical metabolic health platform. The company now works with insurers and employers, offering programs for weight loss, diabetes and diabetes prevention, alongside access to weight-loss medications and psychology-based support, as MedCity News reported. Until now, that stack lacked one ingredient: a continuous stream of physiological signals from members' own bodies. The Noom Band is Noom's answer, built not to compete with fitness trackers on features but to close the loop between daily behavior and clinical outcomes.

Capabilities and Enterprise Business Model

According to Noom's announcement, the band connects activity, sleep, heart rate and HRV trends directly into its behavior-change system. Sensor Bio, the technology partner behind the device, says its sensors and raw-data platform capture heart rate, HRV, SpO2, sleep and activity, with that data flowing into Noom's behavior-science engine. Critically, the band is not sold as a standalone device: it is bundled into existing Noom Health programs, including Weight, Med, Diabetes and DPP, with no additional upfront cost to the payer. Noom has not announced pricing for non-enterprise users or a direct-to-consumer launch.

Integrating Wearable Data into Metabolic Health Programs

The strategic logic centers on Noom Med, the company's obesity care solution that pairs specialized clinicians with integrated lab testing and prescribed medication when clinically necessary, including GLP-1s fulfilled through its SmartRX pharmacy carve-out. Continuous wearable data gives those clinicians and coaches a window into sleep, activity and recovery that periodic check-ins cannot provide. Cook told Fierce Healthcare that integrating a wearable fills a major data gap, and the company sees opportunities to use continuous physiological signals to keep members engaged and drive better outcomes in its weight management and metabolic health programs.

Early Outcome Claims for Connected Wearable Users

Noom released early, company-generated data alongside the announcement — figures that have not been peer-reviewed and should be read as the company's own claims. In Noom's analysis of members taking a GLP-1 medication, those who used a connected wearable were 34% more likely to lose 20 pounds by month four. The company also reported that GLP-1 users with the Noom Band slept an average of 90 more minutes per week after two months, and that members who started with a sleep deficit added 150 minutes of sleep per week. The numbers are directionally suggestive, but they come from Noom's internal analysis rather than an independent study, and no hands-on testing or sensor-accuracy verification accompanies the launch.

Noom Band's Position in the Wearable Market

Noom is explicit that it is not chasing the same customers as Oura or WHOOP. Unlike wearables focused primarily on athletic performance, the company says, the Noom Band is designed to capture measurements related to weight management and metabolic health so members build lasting habits beyond the number on the scale. The table below contrasts the two strategic approaches across the dimensions that matter most to payers and investors.

Noom Band vs. Consumer Wearables: A Strategic Comparison

Noom Band compared with established consumer wearables across four strategic dimensions
AttributeNoom BandEstablished Consumer Wearables
Primary target userMembers of Noom's enterprise metabolic health programs, including those on GLP-1 medicationsConsumers focused on personal performance optimization, including athletes and health enthusiasts
Business modelBundled at no additional upfront cost for Noom Health employer and health plan clients; not sold as a standalone deviceUpfront device cost plus subscription, purchased directly by consumers
Core value propositionDrive better member outcomes and demonstrate ROI for employers and health plans through integrated dataPersonal performance optimization for the individual buyer
Data integrationConnects activity, sleep, heart rate and HRV trends directly into Noom's behavior-change system and clinical programsPrimarily feeds the manufacturer's own consumer app, with limited direct integration into clinical health platforms (a general observation about the category)

The comparison shows the Noom Band positioned not as a rival to athlete-focused devices but as an integrated clinical tool for enterprise health programs — a distinction that shapes everything from its distribution to its success metrics.

Implications for Value-Based Care and ROI

The "no additional cost" model appears designed to remove adoption barriers while supplying the continuous data Noom needs to prove value in outcome-aligned payment arrangements — an inferred strategic intent, but one consistent with Cook's own framing. "We are getting outcomes-based payments, so we believe we will have more people hitting their 5% weight loss goals or 10% weight loss goals, if they have the wearable, than if they don't," Cook told Fierce Healthcare. Noom also plans to participate in CMS's ACCESS model — a 10-year initiative to integrate tech-enabled care into Medicare — under its cardio-kidney-metabolic track, focusing on obesity, prediabetes and diabetes. Cook said Noom intends to bundle the blood pressure cuff and the wearable with its program to maximize effect on measured outcomes like A1C, blood pressure and weight.

Strategic Implications and Future Monitoring

Noom's introduction of the Noom Band signals a clear strategic pivot toward integrated clinical metabolic health solutions for enterprise clients, leveraging continuous biometric data to enhance program effectiveness and demonstrate value. For employers, health plans and investors, the announcement's significance rests on whether the company's early claims hold up under independent scrutiny. Monitor the adoption rates of the Noom Band among enterprise clients and the release of further outcome data, particularly peer-reviewed studies, following its early 2027 launch.

Sources